Related Experiment Videos
Recognition of congestive heart failure due to senile cardiac amyloidosis
M A Gertz1, R A Kyle, W D Edwards
1Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905.
Insights
Senile cardiac amyloidosis, often overlooked, can be diagnosed premortem using endomyocardial biopsy. Early recognition improves survival and guides appropriate treatment, distinguishing it from primary systemic amyloidosis.
Area of Science:
- Cardiology
- Pathology
- Geriatrics
Background:
- Senile cardiac amyloidosis (SCA) was historically considered an incidental autopsy finding in the elderly.
- Autopsy studies revealed significant ventricular amyloid deposits in some elderly individuals, often associated with antemortem congestive heart failure.
- SCA is frequently misdiagnosed premortem, often confused with primary systemic amyloidosis affecting the myocardium.
Purpose of the Study:
- To investigate the premortem diagnosis of senile cardiac amyloidosis.
- To differentiate SCA from primary systemic amyloidosis using novel diagnostic techniques.
- To evaluate the clinical significance and survival outcomes of SCA patients.
Main Methods:
- Utilized endomyocardial biopsy for tissue sampling.
- Employed newly developed immunohistochemical techniques for amyloid characterization.
- Compared clinical presentation and survival data with primary systemic amyloidosis patients.
Main Results:
- Senile cardiac amyloidosis can be recognized premortem.
- Patients with SCA demonstrate longer survival compared to those with primary systemic amyloidosis.
- SCA appears to affect individuals at a younger age than previously suggested by autopsy data.
Conclusions:
- Premortem diagnosis of SCA is feasible and clinically important.
- Distinguishing SCA from primary systemic amyloidosis is crucial for appropriate patient management.
- Patients diagnosed with SCA should not receive treatments intended for primary cardiac amyloidosis.
Abstract:
Senile cardiac amyloidosis has been considered an incidental finding at autopsy in the elderly and of little clinical importance. Autopsy studies have shown that a subset of this group have large deposits of amyloid in their ventricles. Many of these patients had congestive heart failure antemortem. Senile cardiac amyloidosis, however, is rarely diagnosed antemortem and is often confused with primary systemic amyloidosis involving the myocardium. Using endomyocardial biopsy with newly developed immunohistochemical techniques, we have been able to recognize senile cardiac amyloidosis premortem. We have found that these patients have a longer survival than patients with primary systemic amyloidosis. In addition, senile cardiac amyloidosis occurs at a younger age than autopsy studies suggest. Recognition is important because these patients should not be given treatment reserved for the therapy of primary cardiac amyloidosis.